TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules

Molecular Pharmacology

Volumn 79, Issue 1, 2011, Pages 34-41

  Matsunaga, Naoko ^a   Tsuchimori, Noboru ^a   Matsumoto, Tatsumi ^a   Ii, Masayuki ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CD14 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 6; NITRIC OXIDE; RESATORVID; TOLL INTERLEUKIN 1 RECEPTOR DOMAIN CONTAINING ADAPTOR PROTEIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; MEDIATOR RELEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; FEMALE; HEK293 CELLS; HUMANS; MICE; MICE, INBRED BALB C; PROTEIN BINDING; SIGNAL TRANSDUCTION; SULFONAMIDES; TOLL-LIKE RECEPTOR 4;

EID: 78651300299     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.068064     Document Type: Article

References (36)

1. Bartfai T, Behrens MM, Gaidarova S, Pemberton J, Shivanyuk A, and Rebek J Jr (2003) A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc Natl Acad Sci USA 100:7971-7976.
2. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, and Tschopp J (2003) Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 197:263-268.
3. da Silva Correia J and Ulevitch RJ (2002) MD-2 and TLR4 N-linked glycosylations are important for a functional lipopolysaccharide receptor. J Biol Chem 277:1845-1854.
4. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, et al. (2001) Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413:78-83.
5. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha PM, and Golenbock DT (2003) LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 198:1043-1055.
6. Gribar SC, Anand RJ, Sodhi CP, and Hackam DJ (2008) The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation. J Leukocyte Biol 83:493-498.
7. Horng T, Barton GM, and Medzhitov R (2001) TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol 2:835-841.
8. Ii M, Matsunaga N, Hazeki K, Nakamura K, Takashima K, Seya T, Hazeki O, Kitazaki T, and Iizawa Y (2006) A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol 69:1288-1295.
9. Kawamoto T, Ii M, Kitazaki T, Iizawa Y, and Kimura H (2008) TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur J Pharmacol 584:40-48.
10. Khan JA, Brint EK, O'Neill LA, and Tong L (2004) Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL. J Biol Chem 279:31664-31670.
11. Kollewe C, Mackensen AC, Neumann D, Knop J, Cao P, Li S, Wesche H, and Martin MU (2004) Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J Biol Chem 279:5227-5236.
12. Laird MH, Rhee SH, Perkins DJ, Medvedev AE, Piao W, Fenton MJ, and Vogel SN (2009) TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol 85:966-977.
13. Latz E, Visintin A, Lien E, Fitzgerald KA, Monks BG, Kurt-Jones EA, Golenbock DT, and Espevik T (2002) Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem 277:47834-47843.
14. Lee HK, Brown SJ, Rosen H, and Tobias PS (2007) Application of beta-lactamase enzyme complementation to the high-throughput screening of toll-like receptor signaling inhibitors. Mol Pharmacol 72:868-875.
15. Lee JK, Kim SY, Kim YS, Lee WH, Hwang DH, and Lee JY (2009) Suppression of the TRIF-dependent signaling pathway of Toll-like receptors by luteolin. Biochem Pharmacol 77:1391-1400.
16. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, and Hoffmann JA (1996) The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86:973-983.
17. Medvedev AE, Lentschat A, Wahl LM, Golenbock DT, and Vogel SN (2002)) Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol 169:5209-5216.
18. Misko TP, Schilling RJ, Salvemini D, Moore WM, and Currie MG (1993) A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 214:11-16.
19. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, and Billiar TR (2006) Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 26:430-437.
20. Motshwene PG, Moncrieffe MC, Grossmann JG, Kao C, Ayaluru M, Sandercock AM, Robinson CV, Latz E, and Gay NJ (2009) An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. J Biol Chem 284:25404-25411.
21. Nakayama K, Okugawa S, Yanagimoto S, Kitazawa T, Tsukada K, Kawada M, Kimura S, Hirai K, Takagaki Y, and Ota Y (2004) Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages. J Biol Chem 279:6629-6634.
22. Núñez Miguel R, Wong J, Westoll JF, Brooks HJ, O'Neill LA, Gay NJ, Bryant CE, and Monie TP (2007) A dimer of the Toll-like receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins. PloS ONE 2:e788.
23. Nyman T, Stenmark P, Flodin S, Johansson I, Hammarström M, and Nordlund P (2008) The crystal structure of the human toll-like receptor 10 cytoplasmic domain reveals a putative signaling dimer. J Biol Chem 283:11861-11865.
24. O'Neill LA and Bowie AG (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7:353-364.
25. O'Neill LA and Dinarello CA (2000) The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol Today 21:206-209.
26. Oshiumi H, Sasai M, Shida K, Fujita T, Matsumoto M, and Seya T (2003) TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferon-beta. J Biol Chem 278:49751-49762.
27. Park SJ and Youn HS (2010) Isoliquiritigenin suppresses the Toll-interleukin-1 receptor domain-containing adapter inducing interferon-beta (TRIF)-dependent signaling pathway of Toll-like receptors by targeting TBK1. J Agric Food Chem 58:4701-4705.
28. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, and Gerritsen ME (1997) Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272:21096-21103.
29. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, and Beutler B.-Y, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, and Beutler B (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088.
30. Schröder NW and Schumann RR (2005) Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infectious Diseases 5:156-164.
31. Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, and Iizawa Y (2007) Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol 571:231-239.
32. Takashima K, Matsunaga N, Yoshimatsu M, Hazeki K, Kaisho T, Uekata M, Hazeki O, Akira S, Iizawa Y, and Ii M (2009) Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol 157:1250-1262.
33. Tao X, Xu Y, Zheng Y, Beg AA, and Tong L (2002) An extensively associated dimer in the structure of the C713S mutant of the TIR domain of human TLR2. Biochem Biophys Res Commun 299:216-221.
34. Triantafilou M and Triantafilou K (2002) Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 23:301-304.
35. Wietek C, Miggin SM, Jefferies CA, and O'Neill LA (2003) Interferon regulatory factor-3-mediated activation of the interferon-sensitive response element by Toll-like receptor (TLR) 4 but not TLR3 requires the p65 subunit of NF-kappa. J Biol Chem 278:50923-50931.
36. Xu Y, Tao X, Shen B, Horng T, Medzhitov R, Manley JL, and Tong L (2000) Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature 408:111-115.